Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03518112
Terminated
This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as dexamethasone, filgrastim, pegfilgrastim, cyclophosphamide, methotrexate, cytarabine and vincristine sulfate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Register for Updates
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
NCT01575925
Completed
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Colorado Blood Cancer Institute, Denver, Colorado +8 locations
Conditions: Multiple Myeloma, Renal Impairment
Register for Updates
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
NCT02780609
Completed
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
NCT04225611
Unknown
The main aim of the pilot study is to determine preliminary estimates of the safety, tolerability, and comfort of a dexamethasone-eluting therapeutic contact lens drug delivery system (TCL-DDS) for the treatment of recurrent cystoid macular edema. Secondarily, feasibility of the TCL-DDS system will be investigated. 1. Safety: To establish that a topical dexamethasone delivery system has an acceptable safety profile by determining the incidence and severity of ocular adverse events, as identifie... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/27/2022
Locations: MEEI, Boston, Massachusetts
Conditions: Cystoid Macular Edema
Register for Updates
Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04155008
Terminated
Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease the suffering and distress associated with eating during cancer treatment and improve the quality of life of patients by implementing an algorithm utilizing nutrition intervention and appetite stimulants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Montefiore Hospital, Bronx, New York
Conditions: Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Register for Updates
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
NCT03349281
Completed
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
Gender:
ALL
Ages:
Between 16 years and 39 years
Trial Updated:
10/19/2022
Locations: University of Miami, Miami, Florida
Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Register for Updates
Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury
NCT04136743
Unknown
Rotator cuff disease (i.e., rotator cuff tendinopathy or tear) is a common cause of shoulder pain in persons with chronic spinal cord injury (SCI). It usually resolves with non-operative treatments such as pharmacological agents and physical therapy; however, when this fails, rotator cuff surgery may be the only option. Corticosteroid injections are another alternative to provide temporary relief, but can over time accelerate degeneration of the tendon and lead to further damage. Autologous adip... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/12/2022
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Register for Updates
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
NCT02654132
Completed
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2022
Locations: Winship Cancer Institute, Atlanta, Georgia +54 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
NCT00054158
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and thalidomide in treating patients who have newly diagnosed stage I, stage II, or stage III multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/30/2022
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
NCT03236792
Completed
Light chain (AL) amyloidosis is a bone marrow disorder that affects a wide range of organs that can lead to organ dysfunction and death. Amyloid is an abnormal protein that is produced in your bone marrow and cannot be broken down. It builds up in different organs preventing them from working well. The most commonly affected organs are the kidneys, heart, liver, spleen, nervous system, and digestive tract. Treatment with chemotherapy can stop the growth of abnormal cells that produce this abnorm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2022
Locations: Icahn School of Medicine at Mount Sinai, New York, New York +2 locations
Conditions: AL Amyloidosis
Register for Updates
Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries
NCT02980835
Completed
Intercostal nerve block, performed under the guidance of videoscope, is a part of standard anesthesia procedures for patients receiving Video-Assisted Thoracic Surgeries. In this double-blind, prospective, multi-center, randomized, controlled clinical trial the investigators aim to compare preemptive versus post-closure intercostal injection of ropivacaine in controlling post-video-assisted thoracotomy pain.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
09/20/2022
Locations: VA Western New York Healthcare System, Buffalo, New York
Conditions: Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Register for Updates
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
NCT04265534
Terminated
This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are PFS per RECIST v. 1.1 and safety. KEAP1/NRF2 mutation status (for eligibility) and STK11/LKB1 stat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama +101 locations
Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Register for Updates